DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Willoughby, C, Aronson, J, Agback, H, Bodin, N, Andersson, E, Truelove, S
التنسيق:	Journal article
اللغة:	English
منشور في:	1981

مواد مشابهة

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
حسب: Willoughby, C, وآخرون
منشور في: (1982)

Disodium azodisalicylate in ulcerative colitis.
حسب: Jewell, D, وآخرون
منشور في: (1981)

THE DISPOSITION AND METABOLISM OF SULPHASALAZINE (SALICYLAZOSULFAPYRIDINE) IN MAN
حسب: Khan, A, وآخرون
منشور في: (1982)

The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.
حسب: Moraes, M, وآخرون
منشور في: (1991)

Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases
حسب: Irene Mignini, وآخرون
منشور في: (2023-12-01)

Therapeutic efficacy of jeoryeong-tang in dextran sulfate sodium-induced mouse model of inflammatory bowel disease
حسب: Il-Woong Jang, وآخرون
منشور في: (2025-01-01)

Therapeutic targets in inflammatory bowel disease
حسب: Daniela Fluxa, وآخرون
منشور في: (2019-07-01)

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents
حسب: Orazio Palmieri, وآخرون
منشور في: (2024-06-01)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
حسب: Chang Soo Eun
منشور في: (2017-01-01)

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease
حسب: Katie Lloyd, وآخرون
منشور في: (2020-11-01)

Bicervical Normal Uterus with Normal Vagina and Anteroposterior Disposition of the Double Cervix
حسب: José Morales-Roselló, وآخرون
منشور في: (2011-01-01)

The discovery of the foxglove as a therapeutic agent
حسب: Aronson, J
منشور في: (1987)

Therapeutic Drug Monitoring in Inflammatory Bowel Disease
حسب: Manoel Alvaro de Freitas Lins Neto, وآخرون
منشور في: (2023-12-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
حسب: Marafini I, وآخرون
منشور في: (2020-06-01)

Evolving Therapeutic Strategies in the Inflammatory Bowel Disease
حسب: Soo-Young Na, وآخرون
منشور في: (2018-02-01)

Sodium phosphate solution as bowel preparation for outpatient diagnostic and therapeutic manipulations
حسب: N. V. Topchy, وآخرون
منشور في: (2017-12-01)

Advances in biological agents in the treatment of inflammatory bowel disease
حسب: Na LI, وآخرون
منشور في: (2022-08-01)

The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
حسب: Tri Hapsoro Guno, وآخرون
منشور في: (2017-12-01)

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
حسب: Bufu Tang, وآخرون
منشور في: (2020-11-01)

Neurochemical studies in normal volunteers
حسب: Nutt, D, وآخرون
منشور في: (1988)

Translating immunology into therapeutic concepts for inflammatory bowel disease
حسب: Uhlig, HH, وآخرون
منشور في: (2018)

Genetically engineered bacteria as inflammatory bowel disease therapeutics
حسب: Zhen-Ping Zou, وآخرون
منشور في: (2024-12-01)

Ferroptosis: A therapeutic opportunity of inflammatory bowel disease
حسب: Yulin Ye, وآخرون
منشور في: (2024-04-01)

Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease
حسب: Sung Noh Hong
منشور في: (2017-09-01)

Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease
حسب: Qiuyun Xu, وآخرون
منشور في: (2021-03-01)

Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
حسب: Giovanni Pallio
منشور في: (2023-09-01)

Gut microbiome–based therapeutics in inflammatory bowel disease
حسب: Kelly A. Hu, وآخرون
منشور في: (2023-04-01)

Nutritional approach as therapeutic manipulation in inflammatory bowel disease
حسب: Jin Young Yoon
منشور في: (2019-10-01)

The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
حسب: Tao Zuo, وآخرون
منشور في: (2018-09-01)

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases
حسب: Broering MF, وآخرون
منشور في: (2024-04-01)

THE DISPOSITION OF ORAL RUBIDIUM CHLORIDE IN ESSENTIAL-HYPERTENSION
حسب: Boon, N, وآخرون
منشور في: (1982)

The dispositional effects of holidays on investor sentiment: Therapeutic and hygienic
حسب: Qing Liu, وآخرون
منشور في: (2023-04-01)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
حسب: Abdullahi, ST, وآخرون
منشور في: (2019)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
حسب: Jürgen B. Bulitta, وآخرون
منشور في: (2019-07-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
حسب: Al Sulais E, وآخرون
منشور في: (2020-01-01)

Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.
حسب: Mahida, Y, وآخرون
منشور في: (1989)

THE EFFECT OF DIGOXIN ON THE INVIVO DISPOSITION OF AN ORAL LOAD OF RUBIDIUM CHLORIDE
حسب: Aronson, J, وآخرون
منشور في: (1982)

Agentes biológicos en enfermedad inflamatoria intestinal Biological agents in inflammatory bowel disease
حسب: M. Van Domselaar
منشور في: (2008-12-01)

Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials
حسب: Ronaldo Paolo Panganiban, وآخرون
منشور في: (2025-01-01)

Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering
حسب: Jayshree Mishra, وآخرون
منشور في: (2022-01-01)